SITC connectED Patient Portal


Browse online courses and resources for patients by date published, cancer type, or general immunotherapy courses. Click the Additional Patient Resources button to explore more SITC resources for patients..


Collapse 2023 Advances in Cancer Immunotherapy™: Introduction to Biomarkers

Published Date: 06/30/2023

Expiration Date: 06/30/2024

 

Jointly provided by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).

The 2023 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

 

Course Description
This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. The course, Introduction to Biomarkers provides an overview on types of biomarkers and its significance in treatment of cancer. The SME has discussed various findings and outcomes of the clinical trial initiatives related to biomarkers.

 

View all available ACI online offerings at www.sitcancer.org/acionline.

 

Estimated time to complete the activity: 45 minutes

For additional information about the accreditation of this activity, please visit https://partnersed.com

 

Hardware and Software Requirements
SITC ConnectEd requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 
 

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, and other healthcare providers who care for patients with cancer.

                                                                                                                           

Educational Objectives:                                                  

Upon completion of this activity, participants should be able to:

  • Define the term biomarker.
  • Explain the functions of biomarkers.
  • Differentiate the biomarkers based on their types.
  • Describe the use of biomarkers in various cancer treatments.
  • Summarize the challenges of using biomarkers in the treatment of cancer.

 

Faculty and Disclosure of Conflicts of Interest

PACE requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

 

Faculty:

Dr. Paolo A. Ascierto, MD
Director of Department of Melanoma
UOC Melanoma, Immunoterapia Oncologica e Terapie Innovative
Istituto Nazionale Tumori – Fondazione “G. Pascale”
Napoli, Italy

 

The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:

 

Conflicts of Interest:
Researcher: Bristol Myers Squibb, Roche-Genentech, Pfizer, Sanofi
Consultant/Advisor/Speaker: Bristol Myers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Merck Serono, Pierre-Fabre, AstraZeneca, Sun Pharma, Sanofi, Idera, Sandoz, Immunocore, 4SC, Italfarmaco, Nektar, Boehringer-Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, Oncosec, Nouscom, Lunaphore, Seagen, iTeos, Medicenna, Bio-Al Health, ValoTX, Replimmune, Bayer

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The SITC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

 

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Physician Continuing Education

PACE designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

American Board of Internal Medicine Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.75 contact hours.

 

Pharmacy Continuing Education

PACE designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008073-9999-23-162-H01-P)

Type of Activity: Knowledge

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

 

Instructions for Credit

During the period 06/30/2023 through 06/30/2024, participants must read the learning objectives and faculty disclosures and study the educational activity. Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.

Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

 

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


 

Original Course Date: June 30, 2023
On-Demand Release Date: Available Now

Approved Credit:
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • ANCC: 0.75 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • ACPE: 0.75 hours Contact Hour
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2023 Advances in Cancer Immunotherapy™: Introduction to Biomarkers
    Collapse 2023 Advances in Cancer Immunotherapy™: Mechanisms of Immune-related Adverse Events (irAEs)

    Published Date: 06/01/2023

    Expiration Date: 06/01/2024

     

    Jointly provided by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).

    The 2023 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

     

    Course Description
    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. The course, Mechanisms of Immune-related Adverse Events (irAEs) provides an insight into the host factors that increase the risk of irAEs. The course briefly explains the differences in toxicities of CTLA-4 and PD-1 immune checkpoint inhibitors. The two case studies presented in course enables the learners to assess the immune-related response of immunotherapy treatment in a patient.

    View all available ACI online offerings at www.sitcancer.org/acionline.

     

    Estimated time to complete the activity: 45 minutes

    For additional information about the accreditation of this activity, please visit https://partnersed.com

     

    Hardware and Software Requirements
    SITC ConnectEd requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 
     

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses, and other healthcare providers who care for patients with cancer.

                                                                                                                               

    Educational Objectives:                                                  

    Upon completion of this activity, participants should be able to:

    • Explain the Mechanisms of immune related Adverse Events in brief.
    • Describe the other host factors that affect the risk of immune related Adverse Events.
    • Summarize the differences in PD-L1 and CTLA-4 toxicities.
    • Explain the response assessment process in a patient for the immunotherapy treatment.

     

    Faculty and Disclosure of Conflicts of Interest

    PACE requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

    Faculty:

    Pradnya Patil, MD, FACP
    Associate Staff Oncologist
    Taussig Cancer Center, Cleveland Clinic
    Cleveland, OH

    The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:

    Conflicts of Interest:
    Consultant/Advisor/Speaker: AstraZeneca, Jazz Pharmaceuticals

     

    The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The SITC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

     

    Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Education

    PACE designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    American Board of Internal Medicine Maintenance of Certification

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

     

    Nursing Continuing Professional Development

    The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.75 contact hours.

     

    Pharmacy Continuing Education

    PACE designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008073-9999-23-151-H01-P)

    Type of Activity: Knowledge

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

     

    Instructions for Credit

    During the period 06/01/2023 through 06/01/2024 participants must read the learning objectives and faculty disclosures and study the educational activity. Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

     

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

     

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

     

    Original Course Date: May 30, 2023
    On-Demand Release Date: Available Now

    Approved Credit:
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • ANCC: 0.75 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • ACPE: 0.75 hours Contact Hour
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2023 Advances in Cancer Immunotherapy™: Mechanisms of Immune-related Adverse Events (irAEs)
    Collapse 2023 Advances in Cancer Immunotherapy™: Introduction to Immunology

    Published Date: 05/05/2023

    Expiration Date: 05/05/2024

     

     

    Jointly provided by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).

    The 2023 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

     

    Course Description
    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team. The ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future.

    This course, Introduction to Immunology provides an overview of the immune system, focusing on the mechanisms by which the immune system eliminates foreign pathogens and cancer cells. The foundational knowledge presented in this course is critical to understanding how the immune system can be harnessed to treat cancer through immunotherapy.

    View all available ACI online offerings at www.sitcancer.org/acionline.

     

    Estimated time to complete the activity: 1 hour

    For additional information about the accreditation of this activity, please visit https://partnersed.com

     

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 
     

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses, and other healthcare providers who care for patients with cancer.

                                                                                                                               

    Educational Objectives:                                                  

    Upon completion of this activity, participants should be able to:

    • Describe the function of the components of the immune system, including relevant cells, molecules, and organs of the immune system.
    • Differentiate between the adaptive immune system and the innate immune system.
    • Recognize the barriers to effective immunotherapy, including mechanism by which tumors locally disable and/or evade the immune system.

     

    Faculty and Disclosure of Conflicts of Interest

    PACE requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

    Faculty:

    Chrystal M. Paulos, PhD
    Director of Translational Research, Cutaneous Malignancies
    Winship Cancer Institute at Emory University

    The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:

    Conflicts of Interest:
    IP Rights: Ares Immunotherapy
    Consulting Fees: Ares Immunotherapy
    Founder/Owner: Ares Immunotherapy
    Other (subcontracts): Obsidian, Lycera, ThermaFisher

     

    The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The SITC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

     

     

    Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Education

    PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    American Board of Internal Medicine Maintenance of Certification

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

     

    Nursing Continuing Professional Development

    The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hours. Designated for 0.5 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses. 

     

    Pharmacy Continuing Education

    PACE designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008073-9999-23-142-H01-P)

    Type of Activity: Knowledge

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

     

    Instructions for Credit

    During the period 05/05/2023 through 05/05/2024 participants must read the learning objectives and faculty disclosures and study the educational activity. Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

     

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

     

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

     

    Original Course Date: May 05, 2023
    On-Demand Release Date: Available Now

    Approved Credit:
  • : 1 hour AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACCME (non-MD/DO): 1 hour AMA PRA Category 1 Credit(s)™
  • ANCC: 1 hour Contact Hour
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)™
  • ACPE: 1 hour Contact Hour
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2023 Advances in Cancer Immunotherapy™: Introduction to Immunology
    Collapse 2023 Advances in Cancer Immunotherapy™: Basic Principles of Cancer Immunotherapy

    Published: On 04/28/2023

    Please note, this activity does not offer continuing education credit.

    The 2023 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

    Additional support for this activity provided by:

     

    Course Description
    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future.

    This course, Basic Principles of Cancer Immunotherapy will walk the learner through the biological foundations of immunotherapy, types of immunotherapies, illustrate how biomarkers play a major role in immunotherapy, as well as cover the patient response to immunotherapy and subsequent physician assessment.  

    View all available ACI online offerings at www.sitcancer.org/acionline.

     

    Estimated time to complete activity:  1 hour

     

    Target Audience
    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives
    At the conclusion of this activity, the participant should be able to:

    • Describe the concept of Immunotherapy.
    • Identify the various types of cancer immunotherapy.
    • Describe the rationale for common approaches to cancer immunotherapy.
    • Explain the response assessment process in a patient for the immunotherapy treatment.

     

     

    Satisfactory Completion
    Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts) and complete an evaluation form/Survey to receive a certificate of completion.

     

     

    Faculty
    Christian M. Capitini, MD
    Associate Professor
    University of Wisconsin-Madison

    Disclosure of Conflicts of Interest
    The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 
    Christian M. Capitini, MD: Works at a Academic Medical Center and a consultant advisor speaker for Bayer, Elephas, Novartis, Nektar Therapeutics, WiCell Research Institute

    The Society for Immunotherapy of Cancer planners and others have nothing to disclose.

     

    SITC Online Education Disclaimer
    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all the information and data before treating patients or employing any therapies described in this educational activity. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

     

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

     

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


     

     

    Original Course Date: April 28, 2023

    Approved Credit:
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2023 Advances in Cancer Immunotherapy™: Basic Principles of Cancer Immunotherapy
    Collapse 2023 Advances in Cancer Immunotherapy™: Combination Therapies in Combating Cancer

    Published: On 08/11/2023

     

    Please note, this activity does not offer continuing education credit.

    The 2023 Advances in Cancer Immunotherapy™ educational series is supported, in part, through independent medical education grants from AstraZeneca, Bristol Myers Squibb, Exelixis, GSK, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

    Additional support for this activity provided by:

     

    Course Description
    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future.

     

    The course- Combination therapies in Combating Cancer gives a brief overview of the several combination therapies such as Inhibitory Immune Checkpoint Combination therapy, Targeted Immunotherapy approches, and other emerging combination therapies. In this course, the subject matter expert describes the effectiveness of various combination immunotherpy approches and their outcomes in cancer patients using several case studies and research papers. The course content emphasizes the emerging landscape of combining immunotherapy with different modalities to treat cancer. 

     

    View all available ACI online offerings at www.sitcancer.org/acionline.

     

    Estimated time to complete activity:  1 hour

     

    Target Audience
    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives
    At the conclusion of this activity, the participant should be able to:

    • Describe key immunotherapy targets that are useful for combination approaches.
    • Describe immunotherapy-based combination treatment regimens currently under investigation.
    • Discuss the emerging landscape of combining immunotherapy with different modalities to treat cancer.

     

    Satisfactory Completion
    Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts) and complete an evaluation form/Survey to receive a certificate of completion.

     

    Faculty
    Gregory B. Lesinski, PhD, MPH
    Co-Director, Translational GI Malignancy Program
    Winship Cancer Institute of Emory University,
    Atlanta, Georgia, USA

     

    Disclosure of Conflicts of Interest
    The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 
    Gregory B. Lesinski, PhD, MPH: Works at a Academic Medical Center and a consultant advisor speaker for Bristol-Myers Squib, Vaccinex, Boerhinger-Ingelheim, Merck and Co.

    The Society for Immunotherapy of Cancer planners and others have nothing to disclose.

     

    SITC Online Education Disclaimer
    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all the information and data before treating patients or employing any therapies described in this educational activity. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

     

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
     

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
     

    Original Course Date: March 02, 2023

    Approved Credit:
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2023 Advances in Cancer Immunotherapy™: Combination Therapies in Combating Cancer
    Collapse SURVEY: Patient Perspective: Share Your Experiences With Early Cancer Diagnosis and Immunotherapy Treatment

    Access Course

    Patients are encouraged to take this survey to share their experience with early cancer diagnosis and cancer immunotherapy.

     

     

     

     

     

     

     

    Available beginning: February 14, 2023

     

    Approximate Time to Complete: 15 minutes

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: February 14, 2023
    On-Demand Release Date: Available Now
    MORE INFOMORE INFO SURVEY: Patient Perspective: Share Your Experiences With Early Cancer Diagnosis and Immunotherapy Treatment
    Collapse Advanced Kidney Cancer: Know Your Treatment Options

    Access Course

    This article is for people who have advanced kidney cancer and their caregivers, or anyone who wants to learn more about advanced kidney cancer. The goal of this activity is to help people engage in shared decision-making with their doctor about treatment.

     

     

     

     

    In this course, you will learn about:

    • What advanced kidney cancer is
    • Making a treatment plan with your doctor
    • Treatment options for advanced kidney cancer
    • Possible side effects of treatment
    • Questions to ask your doctor

    Available beginning: February 24, 2022

    Approximate Time to Complete: 30 minutes

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: February 24, 2022
    MORE INFOMORE INFO Advanced Kidney Cancer: Know Your Treatment Options
    Collapse Patient Course: Understanding Cancer Immunotherapy - Fifth Edition

    Course Description

    This easy-to-use, interactive course provides patients and caregivers with many resources and basic education on cancer and immunotherapy. The course is designed to be self-directed and is based on the Understanding Cancer Immunotherapy - 5th Edition Patient Resource Guide. There are five modules offered, and learners can access one or all of the modules, depending upon their interest level for each topic: 

     

    first_screen_2.png

     

     

     

     

     

     

     

     

     

     

     

     

    Module Content

    Your Treatment and Providers - This module talks about how cancer treatment may proceed, including what tests a patient may undergo, what doctors may look for to determine the best treatment options, and healthcare providers that are involved in cancer care. It also provides links to SITC resources by type of cancer.

    Cancer and The Immune System - This module provides education on what cancer is, why it forms, how it relates to the immune system as well as how it can evade the immune system. This is a helpful precursor to the Types of Immunotherapy module which explains how different immunotherapies work.

    Types of Immunotherapies - This module has interactive animations that help describe how different types of cancer immunotherapy work to treat cancer. In addition, there is an infographic of the FDA-approved cancer immunotherapies by disease.

    The Importance of Reporting Side Effects - This module discusses possible side effects of cancer immunotherapy and stresses why it is important to report side effects to care providers. It also provides links to more resources on this topic.

    Empower Yourself With Patient Resources - This module has many links to a wide variety of resources, including financial assistance resources, clinical trial search engines, patient/caregiver support groups and more information and courses by disease type.

     

     

    Target Audience

    This activity is intended for cancer patients and their caregivers.

     

    Educational Objectives

    After completing this activity, the participant should:

    • Have an improved understanding of cancer immunotherapy.
    • Be able to find and access support and resources relevant to their cancer and/or situation. 

     

    Available Beginning:  5/30/19

    Approximate time to complete: 30 minutes

     

    This online patient education activity was produced with the generous support of the following companies.

     


    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.




     

    Original Course Date: May 30, 2019
    MORE INFOMORE INFO Patient Course: Understanding Cancer Immunotherapy - Fifth Edition
    Collapse Management of Advanced Bladder Cancer: What You Should Know

    Access Course

     

    This article is for people who have advanced bladder cancer or anyone who wants to learn more about advanced bladder cancer. The goal of this patient education activity is to make patients more aware of available treatment options for advanced bladder cancer.

     

     

     

     

     

    You will learn about:

     

    • What chemotherapy is and how it is used to treat advanced bladder cancer
    • What checkpoint inhibitors are and how they are used to treat advanced bladder cancer
    • The potential side effects of chemotherapy and checkpoint inhibitors
    • Why the side effects from chemotherapy and checkpoint inhibitors are different
    • Questions to ask your doctor

     

    Available beginning: April 26, 2019

     

    Approximate Time to Complete: 30 minutes

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: April 26, 2019
    MORE INFOMORE INFO Management of Advanced Bladder Cancer: What You Should Know


    Patient Courses by Cancer Type